Michael J. Fox Foundation

The Michael J. Fox Foundation is dedicated to ensuring the development of better treatments, and ultimately a cure, for Parkinson’s disease through an aggressively funded research agenda. The foundation has developed a targeted approach to research funding that helps identify and prioritize the science behind reaching its goal of curing Parkinson’s disease.

Deciphera Pharmaceuticals, LLC

Deciphera Pharmaceuticals, LLC was established in 2003 as a drug discovery and development company with the mission to design, optimize and introduce “best-in-class” small molecule Switch Inhibitors of protein kinases for human clinical trials and the global pharmaceutical marketplace through the use of its proprietary drug discovery technology platform, Phylomechanics. 

N30 Pharma

N30 Pharma is a privately held biopharmaceutical company headquartered in Boulder, Colorado. N30 Pharma focuses on the discovery and development of proprietary drugs that provide therapeutic advantage over current treatment for major human diseases such as asthma, COPD and IBD. The Company’s strategy is to focus upon discovery research and early-stage clinical development, and then establish one or more partnerships with leading pharmaceutical companies to further the advancement of its lead clinical candidates.

SomaLogic

SomaLogic is a privately held biomarker discovery and clinical proteomics company based in Boulder, Colorado.  The company’s mission is to use its proprietary SOMAmer technology to develop enhanced protein analysis tools and reagents for the life sciences community, to facilitate target validation, and to develop and commercialize clinical diagnostic products that will improve the delivery of healthcare by offering timely and accurate diagnostic information to physicians and their patients. 

UCB

UCB, Brussels, Belgium (www.ucb-group.com) is a global biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing more than 10 000 people in over 40 countries, UCB expects to achieve revenue of 3.3 billion Euro in 2008.

Accelerated Technologies Center for Gene to 3D Structure

The Accelerated Technologies Center for Gene to 3D Structure (ATCG3D) is an NIH Protein Structure Initiative Specialized Center focused on the accelerated development, integration, and deployment of three emerging technologies (tunable laboratory X-ray source, synthetic gene design, and nanovolume microfluidic crystallization) which have high potential to improve the economics of protein structure determination by X-ray crystallographic methods.

Heptares Therapeutics Ltd.

Heptares Therapeutics Ltd. is a drug discovery company focused on novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs), the largest family of druggable targets. Heptares has developed a unique, transformational and proprietary technology for making purified, stabilised and functional GPCRs (known as StaRs™, Stabilised Receptors), overcoming a major limiting factor to the development of new drugs targeting this group. Heptares’ StaR platform is based on world-class science from the MRC Laboratory of Molecular Biology (Cambridge, UK) and enables the Company to engineer and purify GPCRs in stable and functional conformations that retain their drug-binding characteristics. For the first time, contemporary drug discovery approaches, such as crystallization and structure-based design, biophysical analysis of ligand interactions and fragment screening can now be applied to GPCRs. This unique approach is expected to radically improve the chances of finding drugs to previously intractable targets and will enable the development of safer and more selective therapeutic agents.